GlassScriptPhysician profile
Erin Manoles
NPI 1730544776
$643.70
in general payments reported to CMS, 2019-2025
13 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.38 · 2022: $161 · 2023: $110 · 2024: $175 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $85.70 | 2021-2025 | Cosentyx |
| Janssen Biotech, INC. | $82.61 | 2022-2025 | Tremfya |
| Incyte Corporation | $81.19 | 2021-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $63.61 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $60.29 | 2021-2024 | Libtayo |
| Genzyme Corporation | $58.54 | 2022-2024 | |
| Biofrontera INC. | $52.58 | 2022-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Lilly USA, LLC | $49.17 | 2022-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $31.59 | 2023-2025 | Sotyktu |
| Amgen INC. | $23.94 | 2022 | |
| Kyowa Kirin, INC. | $20.38 | 2024 | Poteligeo |
| Ucb, INC. | $17.17 | 2024 | Bimzelx |
| Dermavant Sciences, INC. | $16.93 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Manoles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.